Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $107.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target hoisted by JPMorgan Chase & Co. from $72.00 to $107.00 in a report issued on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities analysts also recently issued research reports about the company. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Citigroup upped their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday. Canaccord Genuity Group raised their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. One equities research analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $87.38.

Kiniksa Pharmaceuticals International Trading Down 4.9%

KNSA stock opened at $74.34 on Wednesday. Kiniksa Pharmaceuticals International has a 52 week low of $29.90 and a 52 week high of $82.94. The company has a market capitalization of $5.72 billion, a price-to-earnings ratio of 76.64 and a beta of 0.07. The firm’s 50-day moving average is $59.04 and its two-hundred day moving average is $51.13.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting the consensus estimate of $0.30. The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. On average, equities research analysts predict that Kiniksa Pharmaceuticals International will post 1.38 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the transaction, the director directly owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. The trade was a 23.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 51.98% of the stock is owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Rubric Capital Management LP raised its stake in Kiniksa Pharmaceuticals International by 2.3% in the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after acquiring an additional 90,194 shares during the period. Vanguard Group Inc. boosted its position in Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after purchasing an additional 49,802 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in Kiniksa Pharmaceuticals International by 45.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock worth $41,481,000 after purchasing an additional 332,846 shares during the period. Qube Research & Technologies Ltd increased its holdings in shares of Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares during the last quarter. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.